BMF-219

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

Near Add Your Location

Sorting 16 by

Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, CA
  • Accepting patients
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
Northside Hospital (Atlanta)
Atlanta, GA
  • Accepting patients
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
  • Accepting patients
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients
1,327 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.